Immune Reconstitution Inflammatory Syndrome

2
Pipeline Programs
2
Companies
1
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
METHYLPREDNISOLONE SODIUM SUCCINATEApproved
methylprednisolone
Unknown Company
injection2016

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
1 program
1
MethylprednisolonePhase 41 trial
Active Trials
NCT01211665Terminated3Est. Feb 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiogenMethylprednisolone

Clinical Trials (1)

Total enrollment: 3 patients across 1 trials

NCT01211665BiogenMethylprednisolone

Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)

Start: Sep 2010Est. completion: Feb 20123 patients
Phase 4Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space